Studies in patients with chronic granuloeytic leukemia by Rundles et al
Allopurinol, a xanthine oxidase inhibitor, is a urate-lowering medication that is FDA approved for managing gout, preventing tumor lysis syndrome, and preventing recurrent calcium nephrolithiasis in patients
Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate
Introduction
The renal clearance of hypoxanthine and xanthine are ten times higher than that of uric acid
Allopurinol is a xanthine oxidase inhibitor used in the management of gout
Allopurinol reduces serum and urinary uric acid concentrations; its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics
Patients receiving anticancer therapy that results in tumor lysis syndrome sometimes require allopurinol
The genetic mutation causing APL is a chromosomal translocation between chromosomes 15 and 17, which results in creation of a fusion gene, PML/RARA
You may report side effects to FDA at 1-800-FDA-1088
T1 - Allopurinol use during maintenance therapy for acute lymphoblastic leukemia avoids mercaptopurine-related hepatotoxicity
AU - Warwick, Anne B
This build up can be caused by some illnesses or as a side effect of certain medicines
Available limited published data on allopurinol use in In untreated acute myeloid leukemia In parallel, we provide intravenous hydration to ensure adequate urine flow, use allopurinol or rasburicase to reduce serum uric acid levels, and check for signs of DIC or tumor lysis twice daily until the WBC count has fallen below upper normal limits
1965
Use: For the management of patients with leukemia, lymphoma, and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels